Skip to main content

Table 1 Characteristics of melanoma patients and tumors used to evaluate ATP1A1 protein expression by IHC (n = 84)

From: ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy

Parameters

N

Missing values

Median

Range

Gender (female/male)

50/34

0

  

Breslow thickness (≤1/>1)

19/65

0

  

Ulceration of primary (yes/no)

29/55

0

  

Lymph node invasion (1/≥1)

40/23

21

  

Overall survival (years)

80

4

4.85

0.8–28.4

Status (alive/dead)

26/58

0

  
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us